Lipocine Inc. (LPCN)
LPCN Stock Price Chart
Explore Lipocine Inc. interactive price chart. Choose custom timeframes to analyze LPCN price movements and trends.
LPCN Company Profile
Discover essential business fundamentals and corporate details for Lipocine Inc. (LPCN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Oct 2013
Employees
16.00
Website
https://www.lipocine.comCEO
Mahesh V. Patel
Description
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
LPCN Financial Timeline
Browse a chronological timeline of Lipocine Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.40, while revenue estimate is $213.00k.
Earnings released on 7 May 2026
EPS came in at -$0.54 falling short of the estimated -$0.51 by -5.88%, while revenue for the quarter reached $1.19m , beating expectations by +634.75%.
Earnings released on 9 Mar 2026
EPS came in at -$0.34 surpassing the estimated -$0.60 by +43.33%, while revenue for the quarter reached $1.12m , beating expectations by +867.84%.
Earnings released on 6 Nov 2025
EPS came in at -$0.59 falling short of the estimated -$0.56 by -5.36%, while revenue for the quarter reached $114.57k , missing expectations by -51.86%.
Earnings released on 5 Aug 2025
EPS came in at -$0.41 matching the estimated -$0.41, while revenue for the quarter reached $622.85k , beating expectations by +161.70%.
Earnings released on 8 May 2025
EPS came in at -$0.35 matching the estimated -$0.35, while revenue for the quarter reached $93.86k , missing expectations by -73.33%.
Earnings released on 13 Mar 2025
EPS came in at $0.33 surpassing the estimated -$0.40 by +182.50%, while revenue for the quarter reached $3.49m , beating expectations by +33.57%.
Earnings released on 7 Nov 2024
EPS came in at -$0.44 surpassing the estimated -$0.48 by +8.33%.
Earnings released on 8 Aug 2024
EPS came in at -$0.56 surpassing the estimated -$0.78 by +28.21%, while revenue for the quarter reached $89.57k , missing expectations by -69.12%.
Earnings released on 9 May 2024
EPS came in at $0.66 surpassing the estimated -$0.68 by +197.06%, while revenue for the quarter reached $7.62m .
Earnings released on 7 Mar 2024
EPS came in at -$0.42 surpassing the estimated -$0.53 by +20.75%, while revenue for the quarter reached $216.19k .
Earnings released on 8 Nov 2023
EPS came in at -$1.27 falling short of the estimated -$0.57 by -122.81%, while revenue for the quarter reached -$3.12m , missing expectations by -1.12k%.
Earnings released on 10 Aug 2023
EPS came in at -$0.68 falling short of the estimated -$0.64 by -6.25%.
Stock split effective on 12 May 2023
Shares were split 1 : 17 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 May 2023
EPS came in at -$0.68 falling short of the estimated -$0.42 by -61.90%, while revenue for the quarter reached $54.99k , missing expectations by -92.95%.
Earnings released on 10 Mar 2023
EPS came in at -$0.51 falling short of the estimated $0.03 by -1.80k%, while revenue for the quarter reached $500.00k , missing expectations by -61.83%.
Earnings released on 9 Nov 2022
EPS came in at -$0.51 matching the estimated -$0.51.
Earnings released on 8 Aug 2022
EPS came in at -$0.68 matching the estimated -$0.68, while revenue for the quarter reached $500.00k , beating expectations by +94.55%.
Earnings released on 9 May 2022
EPS came in at -$0.68 falling short of the estimated -$0.34 by -100.00%.
Earnings released on 9 Mar 2022
EPS came in at $2.55 surpassing the estimated -$0.85 by +400.00%, while revenue for the quarter reached $16.09m , beating expectations by +192.47%.
Earnings released on 10 Nov 2021
EPS came in at -$0.51 surpassing the estimated -$0.85 by +40.00%, while revenue for the quarter reached $54.99k , missing expectations by -20.63%.
Earnings released on 5 Aug 2021
EPS came in at -$1.36 falling short of the estimated -$0.85 by -60.00%.
LPCN Stock Performance
Access detailed LPCN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
